CP-690,550

Phase 3Small molecule

Pfizer

CP-690,550 is one of 213 small molecule programs targeting Eye Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

212

Competitors

Pipeline

Status by Indication[3][1]

Indication

Eye DiseaseActive, not recruiting

Kidney TransplantActive, not recruiting

Juvenile Idiopathic ArthritisActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

PsoriasisActive, not recruiting

Ulcerative ColitisActive, not recruiting

Psoriatic ArthritisActive, not recruiting

Eye DiseasePhase 2

Active, not recruiting

Kidney TransplantPhase 2

Active, not recruiting

Juvenile Idiopathic ArthritisPhase 1

Active, not recruiting

Rheumatoid ArthritisPhase 3

Active, not recruiting

PsoriasisPhase 3

Active, not recruiting

Ulcerative ColitisPhase 3

Active, not recruiting

Psoriatic ArthritisPhase 3

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

CP-690,550

Pfizer

Phase 3

18 2

Rituxan

Roche

Preclinical

61 3

Orencia

Bristol-Myers Squibb

Preclinical

47 4

Actemra

Enbrel

64 6

Arcoxia

Novartis

Preclinical

4 7

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 8

Ilaris

Novartis

Preclinical

3 9

Actos

Takeda

Preclinical

2 10

Kineret

SSwedish Orphan Biovitrum

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis18 trials

A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis

Completed· Pfizer logo

Pfizer·Phase 2·NCT00976599·29 enrolled

Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis

Completed· Pfizer logo

Pfizer·Phase 2·NCT00413660·509 enrolled

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Completed· Pfizer logo

Pfizer·Phase 3·NCT00661661·487 enrolled

Show 15 more trials

A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis

Completed· Pfizer logo

Pfizer·Phase 2·NCT00550446·386 enrolled

A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis

Completed· Pfizer logo

Pfizer·Phase 3·NCT00853385·717 enrolled

Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

Completed· Pfizer logo

Pfizer·Phase 3·NCT00960440·399 enrolled

Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX

Completed· Pfizer logo

Pfizer·Phase 3·NCT01039688·956 enrolled

A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo

Completed· Pfizer logo

Pfizer·Phase 2·NCT01359150·223 enrolled

A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate

Completed· Pfizer logo

Pfizer·Phase 3·NCT00847613·800 enrolled

Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis

Completed· Pfizer logo

Pfizer·Phase 1·NCT01262118·69 enrolled

Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In Japan

Completed· Pfizer logo

Pfizer·Phase 2·NCT00687193·318 enrolled

Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550

Completed· Pfizer logo

Pfizer·Phase 2·NCT01059864·111 enrolled

A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis

Completed· Pfizer logo

Pfizer·Phase 3·NCT00814307·611 enrolled

Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Completed· Pfizer logo

Pfizer·Phase 3·NCT00413699·4,488 enrolled

Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis

Completed· Pfizer logo

Pfizer·Phase 4·NCT02831855·694 enrolled

Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in Japan

Completed· Pfizer logo

Pfizer·Phase 2·NCT00603512·140 enrolled

A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications

Completed· Pfizer logo

Pfizer·Phase 3·NCT00856544·795 enrolled

Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550

Completed· Pfizer logo

Pfizer··NCT00414661·162 enrolled

Psoriasis9 trials

CP-690-550 Ointment For Chronic Plaque Psoriasis

Completed· Pfizer logo

Pfizer·Phase 2·NCT01246583·71 enrolled

A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis

Completed· Pfizer logo

Pfizer·Phase 3·NCT01276639·901 enrolled

Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

Completed· Pfizer logo

Pfizer·Phase 2·NCT01710046·12 enrolled

Show 6 more trials

Topical CP-690,550 For Chronic Plaque Psoriasis

Completed· Pfizer logo

Pfizer·Phase 2·NCT00678561·81 enrolled

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Completed· Pfizer logo

Pfizer·Phase 3·NCT01186744·666 enrolled

A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Completed· Pfizer logo

Pfizer·Phase 3·NCT01309737·960 enrolled

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Terminated· Pfizer logo

Pfizer·Phase 3·NCT01163253·2,867 enrolled

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis

Completed· Pfizer logo

Pfizer·Phase 3·NCT01815424·266 enrolled

Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed· Pfizer logo

Pfizer·Phase 2·NCT00678210·197 enrolled

Kidney Transplant5 trials

Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients

Completed· Pfizer logo

Pfizer·Phase 2·NCT00483756·338 enrolled

A Study Of CP-690,550 In Stable Kidney Transplant Patients

Completed· Pfizer logo

Pfizer·Phase 1·NCT01710033·28 enrolled

A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients

Completed· Pfizer logo

Pfizer·Phase 2·NCT00106639·61 enrolled

Show 2 more trials

Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

Completed· Pfizer logo

Pfizer·Phase 2·NCT00658359·178 enrolled

Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient

Completed· Pfizer logo

Pfizer·Phase 2·NCT00263328·46 enrolled

Moderate to Severe Crohn's Disease2 trials

A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease

Completed· Pfizer logo

Pfizer·Phase 2·NCT00615199·139 enrolled

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Completed· Pfizer logo

Pfizer·Phase 2·NCT01393626·280 enrolled

Ulcerative Colitis2 trials

A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis

Completed· Pfizer logo

Pfizer·Phase 3·NCT01458574·593 enrolled

Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis

Completed· Pfizer logo

Pfizer·Phase 3·NCT01470612·944 enrolled

16 more indications

Prospective1 trial

A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

Completed· Pfizer logo

Pfizer·Phase 1/2·NCT00784719·327 enrolled

Eye Disease1 trial

A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease

Completed· Pfizer logo

Pfizer·Phase 2·NCT01135511·285 enrolled

Interaction1 trial

CP-690,550 and Midazolam Drug-Drug Interaction Study

Completed· Pfizer logo

Pfizer·Phase 1·NCT00902460·25 enrolled

Monotherapy1 trial

Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks

Completed· Pfizer logo

Pfizer·Phase 2·NCT00147498·264 enrolled

End-Stage Renal Disease1 trial

Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease

Completed· Pfizer logo

Pfizer·Phase 1·NCT01710020·12 enrolled

Hepatic Impairment1 trial

A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function

Completed· Pfizer logo

Pfizer·Phase 1·NCT00969813·18 enrolled

Impaired Renal Function1 trial

Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function

Completed· Pfizer logo

Pfizer·Phase 1·NCT01740362·24 enrolled

Pediatric1 trial

Efficacy Study Of Tofacitinib In Pediatric JIA Population

Completed· Pfizer logo

Pfizer·Phase 3·NCT02592434·225 enrolled

Methotrexate1 trial

Co-Administration Of Methotrexate And CP-690,550

Completed· Pfizer logo

Pfizer·Phase 1·NCT01745055·12 enrolled

Crohn's Disease1 trial

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Completed· Pfizer logo

Pfizer·Phase 2·NCT01470599·150 enrolled

Juvenile Idiopathic Arthritis1 trial

Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)

Completed· Pfizer logo

Pfizer·Phase 1·NCT01513902·26 enrolled

Psoriatic Arthritis1 trial

A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis

Completed· Pfizer logo

Pfizer·Phase 3·NCT01519089·95 enrolled

Tics1 trial

CP-690,550 Pharmacokinetics In Healthy Chinese Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT01101919·12 enrolled

Single Dose1 trial

Pharmacokinetics And Safety Study Of Two CP-690,550 Controlled Release Formulation Following Single Dose In Healthy Volunteers

Completed· Pfizer logo

Pfizer·Phase 1·NCT01185184·12 enrolled

Maintenance Therapy1 trial

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Completed· Pfizer logo

Pfizer·Phase 2·NCT01393899·180 enrolled

Unspecified1 trial

CP-690,550 Thorough QTc Study

Completed· Pfizer logo

Pfizer·Phase 1·NCT01743677·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 52 trial records for CP-690,550. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CP-690,550 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CP-690,550. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

CP-690,550

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis18 trials

Psoriasis9 trials

Kidney Transplant5 trials

Moderate to Severe Crohn's Disease2 trials

Ulcerative Colitis2 trials

Prospective1 trial

Eye Disease1 trial

Interaction1 trial

Monotherapy1 trial

End-Stage Renal Disease1 trial

Hepatic Impairment1 trial

Impaired Renal Function1 trial

Pediatric1 trial

Methotrexate1 trial

Crohn's Disease1 trial

Juvenile Idiopathic Arthritis1 trial

Psoriatic Arthritis1 trial

Tics1 trial

Single Dose1 trial

Maintenance Therapy1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News